FDA Approves Preservative-Free Ketamine Generic

Hospitals and clinics that buy ketamine injection gain a preservative-free option during a shortage that has lasted since 2018.

Updated on Nov. 3, 2026 in Nursing Jobs

Flat-color editorial illustration of a row of unlabeled amber glass vials on a clean tray, one vial set slightly forward, in deep red, cream, and amber.
NRx Pharmaceuticals won FDA approval for a preservative-free generic ketamine injection, adding a second supply option during a shortage that has lasted since 2018. AI Illustration. Upload story photo >

The FDA approved NRx Pharmaceuticals' preservative-free generic ketamine ahead of its November 10 goal date, addressing a ketamine injection shortage that has persisted since 2018. The product is manufactured with partner Nephron Pharmaceuticals and will be supplied to American hospitals and clinics once labeled.

Why it matters

Ketamine injection remains on the FDA drug shortage list, and every currently available product contains benzethonium chloride, which limits options for facilities that need a preservative-free formulation. A second source of supply for a drug used in anesthesia and pain control, including labor and delivery, changes procurement and stocking planning for healthcare operators.

The approval came ahead of the November 10 FDA-announced goal date, against a ketamine injection shortage that has run since 2018 and remains on the FDA drug shortage list. FDA published a maximum daily benzethonium chloride exposure of 1 milligram, and the source does not state when the product will be labeled or shipped.

The players

NRx Pharmaceuticals

A pharmaceutical company that filed the approved generic ketamine and a Citizen Petition seeking removal of benzethonium chloride from the drug.

Nephron Pharmaceuticals

A West Columbia, S.C., manufacturer that produces the preservative-free ketamine in partnership with NRx Pharmaceuticals.

U.S. Food and Drug Administration

The federal agency that regulates drug approvals and shortages, and that approved the product through its Office of Generic Drugs.

The details

NRx Pharmaceuticals manufactured the preservative-free ketamine with partner Nephron Pharmaceuticals in West Columbia, S.C., and the FDA Office of Generic Drugs granted the approval. Every currently available ketamine injection product contains benzethonium chloride, so facilities needing a preservative-free option previously had no approved alternative. The company also filed a Citizen Petition asking the FDA to remove benzethonium chloride from ketamine, and the agency has so far declined to designate that preservative as GRAS.

Timeline

  1. Since 2018: ketamine injection shortage begins.

  2. 1970: ketamine is initially formulated with benzethonium chloride.

  3. November 10, 2026: FDA-announced approval goal date, which the approval beat.

Market Landscape

The approval places a preservative-free generic ketamine on the market through the FDA Office of Generic Drugs, one of the few ways a second supplier enters a shortage-affected injectable. Ketamine is on the FDA drug shortage list, and the Secretary of Health and FDA Commissioner have named it a strategic drug whose supply must be assured.

Facilities that rely on ketamine injection should review their current supply and preservative-free stocking needs as this second source enters the market. Procurement and pharmacy teams should confirm labeling and shipping timelines with their distributors before adjusting orders.

The takeaway

Track the product's labeling and availability, and monitor the Citizen Petition on benzethonium chloride, because either outcome would change which ketamine formulations are available to clinical buyers. Confirm supply plans with pharmacy and procurement staff rather than assuming the shortage has ended.

Further reading

For context on staffing demand in the clinical settings that rely on this anesthetic, see Nursing Jobs.